

Lung Cancer Research
Oncology Specialists, S. C.

For more information about the following research studies, please contact
Oncology Specialists, S. C. Lung Cancer Research Coordinator, Kathy Tolzien,
RN at 847-410-0658.

Neoadjuvant therapy for NSCLC, Principle Investigator – Dr Jacob Bitran

Adjuvant therapy for NSCLC, Principle Investigator – Dr Jacob Bitran

Primary therapy for metastatic NSCLC, Principle Investigator – Dr Chadi Nabhan

“Phase II study evaluating the safety and efficacy of oxaliplatin and docetaxel as
first-line therapy in stage IV or IIIB unresectable NSCLC”

A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the
Efficacy of Docetaxel (TAXOTERE) in Combination With ZD6474 (ZACTIMA)
versus Docetaxel (TAXOTERE) in Combination With Placebo in Patients With
Locally Advanced or Metastatic (Stage IIIB-IV) Non-small Cell Lung Cancer
(NSCLC) after Failure of 1st line Anti-Cancer Therapy (Study D4200C00032) - Dr
Jacob Bitran

HYT105962A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus
Whole Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients
with Brain Metastases from Non-Small Cell Lung Cancer – Dr Jacob Bitran